The 2006 FDA News press release being referred to in 2011 says , Erbitix was apporoved for use of in combination with radiation therapy to treat patients with SCCHNC that cannot be removed by surgery (unresectable). Erbitux was also approved for use alone (monotherapy) to treat patients whose head and neck cancer has spread (metastisized) despite the use of standard chemotherapy.

Two things they are saying here, unresectable tumors, and for use alone for metatastic cancer, despite the use of standard chemo therapy, so it's saying standard chemo should be used first.

Between the two news releases. I did not see Erbitux approval for use as first line, if it was not metatastic, and standard chemotherapy wasn't used first.